ÂÜÀòÂÒÂ×

Barbara Weber, MD, serves as the President and CEO of Tango Therapeutics, a biotechnology company focused on developing innovative cancer treatments since September 2017. In addition, Barbara holds board member positions at FogPharma and REVOLUTION Medicines, and is a Venture Partner at Third Rock Ventures, a prominent healthcare venture firm, since 2015. Barbara's prior experience includes senior roles at Novartis as SVP of Oncology Translational Medicine and GlaxoSmithKline as VP of Oncology. Academically, Barbara has held professorships in medicine and genetics at the University of Pennsylvania and the University of Michigan, and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Barbara received a Doctor of Medicine from the University of Washington and a Bachelor's Degree in Chemistry from the same institution.